^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LuLym-T (autologous activated lymphocytes)

    i
    Other names: ATL
    Associations

    News

    Trials
    Company:
    Lujia Biomedical
    Drug class:
    VEGF inhibitor, Cell replacement
    Related drugs:
    Associations

    News

    Trials
    7ms
    Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=95, Recruiting, Lukas Biomedical Inc. | Trial completion date: Dec 2023 --> Aug 2026 | Trial primary completion date: Dec 2023 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    LuLym-T (autologous activated lymphocytes)
    2years
    Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=95, Recruiting, Lukas Biomedical Inc.
    New P2 trial
    |
    AFP (Alpha-fetoprotein)
    |
    LuLym-T (autologous activated lymphocytes)